An Open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine

Clinical Therapeutics

Volumn 35, Issue 6, 2013, Pages 782-794

  Baird Bellaire, Susan ^a   Behrle, Jessica A ^a   Parker, Vernon D ^a   Patat, Alain ^b   Paul, Jeffrey ^a   Nichols, Alice I ^a  

^a PFIZER INC   (United States)

^b Biotrial   (France)

Author keywords

Desvenlafaxine; Hepatic; Metabolism; Pharmacokinetics; Safety

Indexed keywords

DESVENLAFAXINE; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; NEUROTRANSMITTER UPTAKE INHIBITOR; O-DESMETHYLVENLAFAXINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BRAIN DISEASE; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; LABORATORY TEST; LIVER DYSFUNCTION; MALE; NAUSEA; OPEN STUDY; PHARYNGITIS; PHYSICAL EXAMINATION; QT PROLONGATION; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; VITAL SIGN; VOMITING; ADOLESCENT; CLINICAL TRIAL; DRUG EFFECTS; LIVER; LIVER DISEASE; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; FEMALE; HUMANS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84879463333     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.03.013     Document Type: Article

References (29)

1. Wellbutrin XL [prescribing information] 2008, GlaxoSmithKline, Research Triangle Park, NC.
2. Paxil CR [prescribing information] 2006, GlaxoSmithKline, Research Triangle Park, NC.
3. Zoloft [prescribing information] 2006, Pfizer Inc, New York, NY.
4. Celexa [prescribing information] 2005, Forest Pharmaceuticals, Inc, St. Louis, Mo.
5. Prozac [prescribing information] 2009, Eli Lilly & Co, Indianapolis, Ind.
6. Cymbalta [prescribing information] 2004, Eli Lilly & Co, Indianapolis, Ind.
7. Zanger U.M., Raimundo S., Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:23-37.
8. P450 Drug Interaction Table. Indiana University Division of Clinical Pharmacology Indiana University, Division of Clinical Pharmacology, March 3, 2010, Accessed August 17, 2009. http://medicine.iupui.edu/clinpharm/ddis/table.asp.
9. Gex-Fabry M., Balant-Gorgia A.E., Balant L.P., et al. Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur J Clin Pharmacol 2004, 59:883-891.
10. Sanchez C., Bergqvist P.B., Brennum L.T., et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003, 167:353-362.
11. Sanchez C., Bogeso K.P., Ebert B., et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004, 174:163-176.
12. Muth E.A., Haskins J.T., Moyer J.A., et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986, 35:4493-4497.
13. Eap C.B., Lessard E., Baumann P., et al. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 2003, 13:39-47.
14. Abelo A., Andersson T.B., Antonsson M., et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000, 28:966-972.
15. Pristiq [prescribing information] 2013, Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer Inc, Philadelphia, Pa.
16. Muth E.A., Moyer J.A., Haskins J.T., et al. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991, 23:191-199.
17. Deecher D.C., Beyer C.E., Johnston G., et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006, 318:657-665.
18. Linden C.H., Burns M.J. Poisoning and drug overdose. Harrison's Principles of Internal Medicine 2005, 377-384. McGraw-Hill, New York, NY. 16th ed. D.L. Kasper, E. Braunwald, A.S. Fauci (Eds.).
19. Nichols A.I., Richards L.S., Behrle J.A., et al. The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. Int J Clin Pharmacol Ther 2011, 49:3-13.
20. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. Int Dig Health Legis 1997, 48:231-234.
21. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects World Medical Association, Document 17.C. 6-10-2002, Accessed April 2, 2013. http://www.wma.net/en/30publications/10policies/b3/17c.pdf.
22. Septien-Velez L., Pitrosky B., Padmanabhan S.K., et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007, 22:338-347.
23. DeMartinis N.A., Yeung P.P., Entsuah R., Manley A.L. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007, 68:677-688.
24. Bernardi M., Calandra S., Colantoni A., et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998, 27:28-34.
25. Gagnon L.M., Patten S.B. Major depression and its association with long-term medical conditions. Can J Psychiatry 2002, 47:149-152.
26. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
27. Preskorn S.H., Flockhart D. 2006 guide to psychiatric drug interactions. Prim Psychiatry 2006, 13:35-64.
28. Nichols A.I., Behrle J.A., Richards L.S., et al. The absolute bioavailability of desvenlafaxine in healthy subjects. J Bioequiv Availab 2012, 4:18-23.
29. Eap C.B., Bertel-Laubscher R., Zullino D., et al. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report. Pharmacopsychiatry 2000, 33:112-115.